These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 20029238

  • 1. Growth hormone and the heart in Noonan syndrome.
    Noordam C.
    Horm Res; 2009 Dec; 72 Suppl 2():49-51. PubMed ID: 20029238
    [Abstract] [Full Text] [Related]

  • 2. Noonan syndrome: growth to growth hormone - the experience of observational studies.
    Ranke MB.
    Horm Res; 2009 Dec; 72 Suppl 2():36-40. PubMed ID: 20029235
    [Abstract] [Full Text] [Related]

  • 3. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
    Savage MO, Padidela R, Kirk JM, Malaquias AC, Jorge AA.
    Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
    [Abstract] [Full Text] [Related]

  • 4. Noonan syndrome: introduction and basic clinical features.
    Rohrer T.
    Horm Res; 2009 Dec; 72 Suppl 2():3-7. PubMed ID: 20029230
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone therapy in Noonan syndrome: growth response and characteristics.
    Westphal O.
    Horm Res; 2009 Dec; 72 Suppl 2():41-5. PubMed ID: 20029236
    [Abstract] [Full Text] [Related]

  • 6. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
    Binder G.
    Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
    [Abstract] [Full Text] [Related]

  • 7. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
    Kobayashi T, Aoki Y, Niihori T, Cavé H, Verloes A, Okamoto N, Kawame H, Fujiwara I, Takada F, Ohata T, Sakazume S, Ando T, Nakagawa N, Lapunzina P, Meneses AG, Gillessen-Kaesbach G, Wieczorek D, Kurosawa K, Mizuno S, Ohashi H, David A, Philip N, Guliyeva A, Narumi Y, Kure S, Tsuchiya S, Matsubara Y.
    Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
    [Abstract] [Full Text] [Related]

  • 8. GH therapy in Noonan syndrome: Review of final height data.
    Dahlgren J.
    Horm Res; 2009 Dec; 72 Suppl 2():46-8. PubMed ID: 20029237
    [Abstract] [Full Text] [Related]

  • 9. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
    Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ.
    Eur J Endocrinol; 2008 Sep; 159(3):203-8. PubMed ID: 18562489
    [Abstract] [Full Text] [Related]

  • 10. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
    Sznajer Y, Keren B, Baumann C, Pereira S, Alberti C, Elion J, Cavé H, Verloes A.
    Pediatrics; 2007 Jun; 119(6):e1325-31. PubMed ID: 17515436
    [Abstract] [Full Text] [Related]

  • 11. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
    Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA.
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
    [Abstract] [Full Text] [Related]

  • 12. [New findings in Noonan syndrome and Leopard syndrome: activating mutations in RAF-1 and SOS-1].
    Dereure O.
    Ann Dermatol Venereol; 2008 Sep; 135(8-9):624-5. PubMed ID: 18789305
    [No Abstract] [Full Text] [Related]

  • 13. Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients.
    Ferreira LV, Souza SC, Montenegro LR, Malaquias AC, Arnhold IJ, Mendonca BB, Jorge AA.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):426-31. PubMed ID: 18331608
    [Abstract] [Full Text] [Related]

  • 14. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
    Mutesa L, Pierquin G, Janin N, Segers K, Thomée C, Provenzi M, Bours V.
    Cancer Genet Cytogenet; 2008 Apr 01; 182(1):40-2. PubMed ID: 18328949
    [Abstract] [Full Text] [Related]

  • 15. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
    Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, Mizuno K, Tokuyama M, Hirota H, Muneuchi J, Higashinakagawa T, Matsuoka R.
    Nat Genet; 2007 Aug 01; 39(8):1013-7. PubMed ID: 17603482
    [Abstract] [Full Text] [Related]

  • 16. Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy.
    McWilliams GD, SantaCruz K, Hart B, Clericuzio C.
    Am J Med Genet A; 2016 Jan 01; 170A(1):195-201. PubMed ID: 26377682
    [Abstract] [Full Text] [Related]

  • 17. Pilocytic astrocytoma in a child with Noonan syndrome.
    Schuettpelz LG, McDonald S, Whitesell K, Desruisseau DM, Grange DK, Gurnett CA, Wilson DB.
    Pediatr Blood Cancer; 2009 Dec 01; 53(6):1147-9. PubMed ID: 19621452
    [Abstract] [Full Text] [Related]

  • 18. Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation.
    Choi JH, Lee BH, Jung CW, Kim YM, Jin HY, Kim JM, Kim GH, Hwang JS, Yang SW, Lee J, Yoo HW.
    Horm Res Paediatr; 2012 Dec 01; 77(6):388-93. PubMed ID: 22777296
    [Abstract] [Full Text] [Related]

  • 19. [The Noonan syndrome from a pediatric perspective].
    Noordam C, Thoonen G, van der Burgt CJ.
    Ned Tijdschr Geneeskd; 2003 Apr 05; 147(14):644-8. PubMed ID: 12712646
    [Abstract] [Full Text] [Related]

  • 20. Atypical granular cell tumor occurring in an individual with Noonan syndrome treated with growth hormone.
    Moos D, Droitcourt C, Rancherevince D, Marec Berard P, Skowron F.
    Pediatr Dermatol; 2012 Apr 05; 29(5):665-6. PubMed ID: 22329457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.